FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1260-1261 April 24, 1997 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Kovacs, J. A. Related Article by Kovacs, J. A. PubMed Citation

To the Editor: Kovacs et al. (Oct. 31 issue)¹ report that the administration of interleukin-2 (18 million IU per day for five days every two months) in patients with human immunodeficiency virus (HIV) infection resulted in progressive increases in CD4 T cells (an increase of 36.7 cells per cubic millimeter per month) without an increase in plasma HIV RNA levels. However, the authors fail to emphasize how toxic this treatment regimen is.

The dose-limiting side effects include capillary leak, severe influenza-like symptoms, hepatic and renal dysfunction, thrombocytopenia, and neutropenia.^1,2 In their earlier study,² Kovacs et al. found marked viral elevations, . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.